1. Healthy subjects aged 18 years and above who are capable of providing legal identities. Both males and females should be included, 2. The subjects shall fully understand the content of the informed consent form and the study procedure of this clinical trial. The subjects shall voluntarily sign the informed consent form. The subjects shall be capable of using the thermometer and scale, as well as filling in the Diary Card/Contact Card as required, 3. The subjects shall be able to communicate well with the investigators, as well as understand and comply with the requirements of this study, 4. For female subjects of childbearing potential, effective contraception should be used within 2 weeks prior to participation in this study and the pregnancy test is required to be negative (those with amenorrhea of at least 1 year or surgical sterilization verified by medical records could be exempted from the pregnancy test). Participants should voluntarily agree to continue using at least one effective method of contraception for 12 months after complete series (effective methods include oral contraceptives, injectable or implantable contraceptives, sustained-release topical contraceptives, hormonal patches, intrauterine device, sterilization, abstinence, condoms (for males), diaphragms, cervical caps, etc.), 5. Axillary temperature <37.3? on the day of administration.

1. Healthy subjects aged 18 years and above who are capable of providing legal identities. Both males and females should be included, 2. The subjects shall fully understand the content of the informed consent form and the study procedure of this clinical trial. The subjects shall voluntarily sign the informed consent form. The subjects shall be capable of using the thermometer and scale, as well as filling in the Diary Card/Contact Card as required, 3. The subjects shall be able to communicate well with the investigators, as well as understand and comply with the requirements of this study, 4. For female subjects of childbearing potential, effective contraception should be used within 2 weeks prior to participation in this study and the pregnancy test is required to be negative (those with amenorrhea of at least 1 year or surgical sterilization verified by medical records could be exempted from the pregnancy test). Participants should voluntarily agree to continue using at least one effective method of contraception for 12 months after complete series (effective methods include oral contraceptives, injectable or implantable contraceptives, sustained-release topical contraceptives, hormonal patches, intrauterine device, sterilization, abstinence, condoms (for males), diaphragms, cervical caps, etc.), 5. Axillary temperature <37.3? on the day of administration.

1. Healthy subjects aged 18-59 years as well as 60 years and above who are capable of providing legal identities. Both males and females should be included, 2. The subjects shall fully understand the content of the informed consent form and the study procedure of this clinical trial. The subjects shall voluntarily sign the informed consent form. The subjects shall be capable of using the thermometer and scale, as well as filling in the Diary Card/Contact Card as required, 3. The subjects shall be able to communicate well with the investigators, as well as understand and comply with the requirements of this study, 4. For female subjects of childbearing potential, effective contraception should be used within 2 weeks prior to participation in this study and the pregnancy test is required to be negative (those with amenorrhea of at least 1 year or surgical sterilization verified by medical records could be exempted from the pregnancy test). Participants should voluntarily agree to continue using at least one effective method of contraception for 12 months after complete series (effective methods include oral contraceptives, injectable or implantable contraceptives, sustained-release topical contraceptives, hormonal patches, intrauterine device, sterilization, abstinence, condoms (for males), diaphragms, cervical caps, etc.), 5. Axillary temperature <37.3? on the day of administration.

1. Healthy subjects aged 18-59 years as well as 60 years and above who are capable of providing legal identities. Both males and females should be included, 2. The subjects shall fully understand the content of the informed consent form and the study procedure of this clinical trial. The subjects shall voluntarily sign the informed consent form. The subjects shall be capable of using the thermometer and scale, as well as filling in the Diary Card/Contact Card as required, 3. The subjects shall be able to communicate well with the investigators, as well as understand and comply with the requirements of this study, 4. For female subjects of childbearing potential, effective contraception should be used within 2 weeks prior to participation in this study and the pregnancy test is required to be negative (those with amenorrhea of at least 1 year or surgical sterilization verified by medical records could be exempted from the pregnancy test). Participants should voluntarily agree to continue using at least one effective method of contraception for 12 months after complete series (effective methods include oral contraceptives, injectable or implantable contraceptives, sustained-release topical contraceptives, hormonal patches, intrauterine device, sterilization, abstinence, condoms (for males), diaphragms, cervical caps, etc.), 5. Axillary temperature <37.3? on the day of administration.